https://www.selleckchem.com/products/OSI-906.html
Trends to improved pain, appetite and nausea were observed following SBRT. Less than half of patients reported stable or better EORTC global QoL at 1 week. For all other QoL and symptom scales, most patients had reported stable or better scores at all times, with a slight proportional improvement in emotional functioning, nausea, fatigue, pain and appetite, and a slight worsening of physical functioning and dyspnoea over time. SBRT results in well-preserved QoL in the weeks to months following treatment for primary kidney cancer. SBRT r
Like
Comment
Share
